Most recent papers in the journal European Journal of Cancer

#1

JOURNAL ARTICLE

Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.

Pasquale Rescigno, Nuria Porta, Laura Finneran, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Penny Flohr, Susana Miranda, Claudia Bertan, Ana Ferreira, Mateus Crespo, Daniel Nava Rodrigues, Bora Gurel, Jenny Nobes, Simon Crabb, Zafar Malik, Christy Ralph, Ursula McGovern, Peter Hoskin, Robert J Jones, Alison Birtle, Joanna Gale, Peter Sankey, Suneil Jain, Duncan McLaren, Eliot Chadwick, Aude Espinasse, Emma Hall, Johann de Bono

BACKGROUND: PTEN loss and aberrations in PI3K/AKT signaling kinases associate with poorer response to abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). In this study, we assessed antitumor activity of the AKT inhibitor capivasertib combined with enzalutamide in mCRPC with prior progression on AA and docetaxel. METHODS: This double-blind, placebo-controlled, randomized phase 2 trial, recruited men ≥ 18 years with progressing mCRPC and performance status 0-2 from 15 UK centers...

38729054

May 8, 2024: European Journal of Cancer

#2

JOURNAL ARTICLE

ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?

Ughur Aghamaliyev, Javad Karimbayli, Clemens Giessen-Jung, Ilmer Matthias, Kristian Unger, Dorian Andrade, Felix O Hofmann, Maximilian Weniger, Martin K Angele, C Benedikt Westphalen, Jens Werner, Bernhard W Renz

OBJECTIVES: This study aimed to assess the consistency and replicability of treatment recommendations provided by ChatGPT 3.5 compared to gastrointestinal tumor cases presented at multidisciplinary tumor boards (MTBs). It also aimed to distinguish between general and case-specific responses and investigated the precision of ChatGPT's recommendations in replicating exact treatment plans, particularly regarding chemotherapy regimens and follow-up protocols. MATERIAL AND METHODS: A retrospective study was carried out on 115 cases of gastrointestinal malignancies, selected from 448 patients reviewed in MTB meetings...

38729055

May 7, 2024: European Journal of Cancer

#3

LETTER

A fatal case of 5-FU toxicity despite dose adjustment in a patient with a partial DPD deficiency receiving the FLOT regimen.

Aziz Zaanan, Nicolas Pallet, Céline Narjoz, Marie-Anne Loriot, Émilie Hafliger

No abstract text is available yet for this article.

38723381

May 6, 2024: European Journal of Cancer

#4

JOURNAL ARTICLE

Timothée Olivier, Alyson Haslam, Vinay Prasad

Health-related quality-of-life (HRQoL) data are central to capturing the quality of patients' life, while endpoints like overall survival (OS) focus on the quantity of life. When analyzing HRQoL data gathered from patients in a randomized trial, a key consideration is the completion rate - indicating the proportion of patients remaining in the trial and with completed questionnaires. When completion rates are disproportionately low in one treatment arm, one likely explanation is that patients who did not complete questionnaires suffered more from toxicities, negatively impacting their HRQoL...

38718724

May 6, 2024: European Journal of Cancer

#5

JOURNAL ARTICLE

High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma.

Niklas Klümper, Alexander Cox, Markus Eckstein, Christoph Kuppe, Manuel Ritter, Peter Brossart, Julian Luetkens, Michael Hölzel, Johannes Stein, Jonas Saal

OBJECTIVES: The development of reliable biomarkers for the prediction of immune checkpoint inhibition (ICI) response in patients with metastatic renal cell carcinoma (mRCC) and urothelial carcinoma (mUC) remains an unresolved challenge. Conventional ICI biomarkers typically focus on tumor-related factors such as PD-L1 expression. However, a comprehensive evaluation of the predictive value of serum electrolyte levels, a so far widely unexplored area, is still pending. METHODS: We conducted a post-hoc analysis of baseline sodium, potassium, chloride, magnesium and calcium levels in two independent phase 3 clinical trials: IMvigor211 for mUC comparing atezolizumab to chemotherapy, and IMmotion151 for mRCC comparing atezolizumab+bevacizumab to sunitinib...

38703618

April 28, 2024: European Journal of Cancer

#6

JOURNAL ARTICLE

Germline NGS targeted analysis in adult patients with sporadic adrenocortical carcinoma.

Maria Scatolini, Salvatore Grisanti, Pasquale Tomaiuolo, Enrico Grosso, Vittoria Basile, Deborah Cosentini, Soraya Puglisi, Marta Laganà, Paola Perotti, Laura Saba, Elisa Rossini, Flavia Palermo, Sandra Sigala, Marco Volante, Alfredo Berruti, Massimo Terzolo

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare cancer that arises sporadically or due to hereditary syndromes. Data on germline variants (GVs) in sporadic ACC are limited. Our aim was to characterize GVs of genes potentially related to adrenal diseases in 150 adult patients with sporadic ACC. METHODS: This was a retrospective analysis of stage I-IV ACC patients with sporadic ACC from two reference centers for ACC in Italy. Patients were included in the analysis if they had confirmed diagnosis of ACC, a frozen peripheral blood sample and complete clinical and follow-up data...

38714106

April 26, 2024: European Journal of Cancer

#7

JOURNAL ARTICLE

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

Dirk Schadendorf, Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Naoya Yamazaki, Paola Queirolo, Carolin Guenzel, Anna Polli, Mahgull Thakur, Alessandra di Pietro, Paolo A Ascierto

BACKGROUND: Treatment with encorafenib plus binimetinib and encorafenib monotherapy is associated with improved progression-free survival (PFS) and overall survival (OS) compared with vemurafenib in patients with BRAF V600E/K-mutant metastatic melanoma. We report results from the 7-year analysis of COLUMBUS part 1 (NCT01909453) at 99.7 months (median duration between randomization and data cutoff). METHODS: 577 patients with locally advanced unresectable or metastatic BRAF V600E/K-mutant melanoma who were treatment-naive or progressed after first-line immunotherapy were randomized 1:1:1 to encorafenib 450 mg once daily (QD) plus binimetinib 45 mg twice daily (BID) (n = 192), vemurafenib 960 mg BID (n = 191), or encorafenib monotherapy 300 mg QD (n = 194)...

38723373

April 24, 2024: European Journal of Cancer

#8

JOURNAL ARTICLE

Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

Claus Garbe, Ana-Maria Forsea, Teresa Amaral, Petr Arenberger, Philippe Autier, Marianne Berwick, Brigitta Boonen, Matilda Bylaite, Veronique Del Marmol, Brigitte Dreno, Maria Concetta Fargnoli, Alan C Geller, Adele C Green, Rüdiger Greinert, Axel Hauschild, Catherine A Harwood, Isabelle Hoorens, Lidija Kandolf, Roland Kaufmann, Nicole Kelleners-Smeets, Aimilios Lallas, Celeste Lebbé, Ulrike Leiter, Henry W Lim, Caterina Longo, Joseph Malvehy, David Moreno, Giovanni Pellacani, Ketty Peris, Caroline Robert, Philippe Saiag, Dirk Schadendorf, H Peter Soyer, Eggert Stockfleth, Alex Stratigos, Hisashi Uhara, Ricardo Vieira, Beate Volkmer, Martin A Weinstock, Dagmar Whitaker, Iris Zalaudek, David C Whiteman, Lieve Brochez

Cancers of the skin are the most commonly occurring cancers in humans. In fair-skinned populations, up to 95% of keratinocyte skin cancers and 70-95% of cutaneous melanomas are caused by ultraviolet radiation and are thus theoretically preventable. Currently, however, there is no comprehensive global advice on practical steps to be taken to reduce the toll of skin cancer. To address this gap, an expert working group comprising clinicians and researchers from Africa, America, Asia, Australia, and Europe, together with learned societies (European Association of Dermato-Oncology, Euromelanoma, Euroskin, European Union of Medical Specialists, and the Melanoma World Society) reviewed the extant evidence and issued the following evidence-based recommendations for photoprotection as a strategy to prevent skin cancer...

38691877

April 24, 2024: European Journal of Cancer

#9

JOURNAL ARTICLE

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis.

Michael Stucki, Stephanie Dosch, Markus Gnädinger, Sereina M Graber, Carola A Huber, Golda Lenzin, Räto T Strebel, Daniel R Zwahlen, Aurelius Omlin, Simon Wieser

BACKGROUND: Prostate cancer (PC) is the most prevalent cancer in men in Switzerland. However, evidence on the real-world health care use of PC patients is scarce. The aim of this study is to describe health care utilization, treatment patterns, and medical costs in PC patients over a period of five years (2014-2018). METHOD: We used routinely collected longitudinal individual-level claims data from a major provider of mandatory health insurance in Switzerland. Due to the lack of diagnostic coding in the claims data, we identified treated PC patients based on the treatments received...

38678761

April 24, 2024: European Journal of Cancer

#10

Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].

Emilie Le Rhun, Thierry Gorlia, Jörg Felsberg, Joost Jongen, Claude-Alain Maurage, François Ducray, Dorothee Gramatzki, Peter Hau, Olivier L Chinot, Matthias Preusser, Stephanie Cartalat, Patrick Roth, Martin van den Bent, Julia Furtner, Maike Collienne, Guido Reifenberger, Michael Weller

No abstract text is available yet for this article.

38658199

April 23, 2024: European Journal of Cancer

#11

JOURNAL ARTICLE

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study.

Marion Subklewe, Giulia Magno, Christina Gebhardt, Veit Bücklein, Franziska Szelinski, Héctor Julián Rincón Arévalo, Gerulf Hänel, Thomas Dörner, Gerhard Zugmaier, Michael von Bergwelt-Baildon, Alla Skapenko, Hendrik Schulze-Koops

Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation. This inflammatory milieu not only drives the immune dysregulation characteristic of autoimmune diseases but also plays a pivotal role in the pathogenesis of cancer. Among the cellular components involved, B cells have emerged as key players in hematologic tumor and autoimmune disease, contributing to immune dysregulation and persistent tissue fibrosis in systemic sclerosis, as well as tumor progression and immune evasion in cancer...

38691878

April 22, 2024: European Journal of Cancer

#12

LETTER

Incomplete DPYD haplotype B3 in a patient with locally advanced gastric cancer: Reconsidering the 5-FU dosage strategy.

Sascha Dierks, Sören Matthias Buchholz, Alexander König, Torsten Liersch, Julie Schanz

No abstract text is available yet for this article.

38663223

April 20, 2024: European Journal of Cancer

#13

JOURNAL ARTICLE

N0 neck trial: Does intensification of follow-up (Ultrasound + Physical Examination) influence outcomes in early-stage oral cancer?

Richa Vaish, Rohini Hawaldar, Sudeep Gupta, Mitali Dandekar, Snehal Shah, Devendra Chaukar, Gouri Pantvaidya, Anuja Deshmukh, Pankaj Chaturvedi, Prathamesh Pai, Deepa Nair, Sudhir Nair, Meenakshi Thakur, Sarbani Ghosh-Laskar, J P Agarwal, Anil K D'Cruz

AIM OF THE STUDY: We previously reported a survival benefit of elective neck dissection (END) over therapeutic neck dissection (TND) in patients with clinically node-negative early-stage oral cancer. We now report the results of the second question in the same study addressing the impact of adding neck ultrasound to physical examination during follow-up on outcomes. METHODS: Patients with lateralized T1/T2 oral squamous cell carcinoma (SCC) were randomized to END or TND and to follow-up with physical-examination plus neck ultrasound (PE+US) versus physical-examination (PE)...

38705028

April 16, 2024: European Journal of Cancer

#14

JOURNAL ARTICLE

European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4).

Tiuri E Kroese, Sebastiaan Bronzwaer, Peter S N van Rossum, Sebastian F Schoppman, Pieter R A J Deseyne, Eric van Cutsem, Karin Haustermans, Philippe Nafteux, Melissa Thomas, Radka Obermannova, Hanna R Mortensen, Marianne Nordsmark, Per Pfeiffer, Anneli Elme, Antoine Adenis, Guillaume Piessen, Christiane J Bruns, Florian Lordick, Ines Gockel, Markus Moehler, Cihan Gani, Theodore Liakakos, John V Reynolds, Alessio G Morganti, Riccardo Rosati, Carlo Castoro, Francesco Cellini, Domenico D'Ugo, Franco Roviello, Maria Bencivenga, Giovanni de Manzoni, Mark I van Berge Henegouwen, Maarten C C M Hulshoff, Jolanda van Dieren, Marieke Vollebergh, Johanna W van Sandick, Paul Jeene, Christel Muijs, Marije Slingerland, Francine E M Voncken, Henk Hartgrink, Geert-Jan Creemers, Maurice J C van der Sangen, Grard A P Nieuwenhuijzen, Maaike Berbee, Marcel Verheij, Bas Wijnhoven, Laurens V Beerepoot, Nadia Haj Mohammad, Stella Mook, Jelle P Ruurda, Piotr Kolodziejczyk, Wojciech P Polkowski, Lucjan Wyrwicz, Maria Alsina, Josep Tabernero, Manuel Pera, Tania F Kanonnikoff, Andrés Cervantes, Magnus Nilsson, Stefan Monig, Anna D Wagner, Matthias Guckenberger, Ewen A Griffiths, Elizabeth Smyth, George B Hanna, Sheraz Markar, M Asif Chaudry, Maria A Hawkins, Edward Cheong, Hanneke W M van Laarhoven, Richard van Hillegersberg

INTRODUCTION: The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD). METHODS: Guidelines were developed according to AGREE II and GRADE principles. Guidelines were based on a systematic review (OMEC-1), clinical case discussions (OMEC-2), and a Delphi consensus study (OMEC-3) by 49 European expert centers for esophagogastric cancer...

38678762

April 16, 2024: European Journal of Cancer

#15

JOURNAL ARTICLE

Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.

Pierre-Louis Cariou, Cédric Pobel, Jean-Marie Michot, François-Xavier Danlos, Benjamin Besse, Franck Carbonnel, Xavier Mariette, Aurélien Marabelle, Sabine Messayke, Caroline Robert, Emilie Routier, Nicolas Noël, Olivier Lambotte

BACKGROUND: Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs. OBJECTIVE: To investigate the relationship between the use of steroids and/or ISs and overall survival (OS) and progression-free survival (PFS) among ICB-treated patients with an irAE...

38643707

April 14, 2024: European Journal of Cancer

#16

JOURNAL ARTICLE

A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.

Michele Bollino, Barbara Geppert, Celine Lönnerfors, Jan Persson

AIM: To evaluate the locations of metastatic pelvic sentinel nodes (SLN) and the proportion of SLNs outside and within defined typical anatomical positions along the upper paracervical lymphatic pathway (UPP). PATIENTS AND METHODS: Consecutive women with endometrial cancer (EC) of all risk groups underwent pelvic SLN-detection using cervically injected indocyanine green (ICG). A strict anatomically based algorithm and definitions of SLNs was adhered to. The positions of ICG-defined SLNs were intraoperatively depicted on an anatomical chart...

38657525

April 12, 2024: European Journal of Cancer

#17

JOURNAL ARTICLE

Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).

Etienne Lengliné, Joachim Baba, Paul de Boissieu, Alexandre Beaufils, Alice Desbiolles, Thierno Diatta, Pierre Cochat, Sylvie Chevret

BACKGROUND: The use of right-censored composite endpoints, such as progression-free survival, has been questioned in haemato-oncology trials due to potential bias in estimated treatment effect. This may impact the accuracy of health technology evaluations. We hypothesized that there is heterogeneity and potential sources of bias in the reporting of composite endpoints to health technology assessment (HTA) bodies. METHODS: We reviewed the submissions for reimbursement of oncology drugs in 2021 and 2022 that used a composite endpoint in the pivotal trial, after appraisal by the French HTA body...

38653034

April 12, 2024: European Journal of Cancer

#18

JOURNAL ARTICLE

Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.

Elena Guerini-Rocco, Federica Bellerba, Alberto Concardi, Sergio Vincenzo Taormina, Giulio Cammarata, Caterina Fumagalli, Aliana Guerrieri-Gonzaga, Debora Macis, Eliza Del Fiol Manna, Emanuela Balladore, Maria Cannone, Paolo Veronesi, Nicola Fusco, Bernardo Bonanni, Giuseppe Viale, Massimo Barberis, Sara Gandini, Matteo Lazzeroni

BACKGROUND AND AIM: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast cancer recurrence. METHODS: A retrospective nested case-control study of 143 pure DCIS was performed including 70 women with subsequent ipsilateral breast event (IBE, in situ or invasive; cases) and 73 DCIS women with no IBE and matched for age, tumor size, treatment, hormone receptors/HER2 status, and follow-up time (controls)...

38615592

April 12, 2024: European Journal of Cancer

#19

Corrigendum to "Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours" [Eur J Cancer 188 (2023) 39-48].

Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, Eric Raymond, Philippe Ruszniewski, Matthew H Kulke, Enrique Grande, Rocío García Carbonero, Daniel Castellano, Ramón Salazar, Toni Ibrahim, Alex Teule, Vicente Alonso, Nicola Fazio, Juan W Valle, Salvatore Tafuto, Ana Carmona, Victor Navarro, Jaume Capdevila

No abstract text is available yet for this article.

38609739

April 11, 2024: European Journal of Cancer

#20

EDITORIAL

Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions.

Samer Al Hadidi

No abstract text is available yet for this article.

38604006

April 9, 2024: European Journal of Cancer